Cromatina/Epigenética
Os inibidores de cromatina/epigenética são compostos que modulam a estrutura e função da cromatina ou interferem em modificações epigenéticas, como a metilação do DNA e a modificação de histonas. Esses inibidores são ferramentas essenciais para estudar a regulação da expressão gênica e o papel da epigenética em doenças como o câncer, distúrbios neurológicos e anomalias do desenvolvimento. Ao direcionar os processos epigenéticos, esses inibidores podem alterar os padrões de expressão gênica e oferecer novas vias terapêuticas. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de cromatina/epigenética de alta qualidade para apoiar sua pesquisa em biologia molecular, genética e epigenética.
Subcategorias de "Cromatina/Epigenética"
Foram encontrados 2235 produtos de "Cromatina/Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PF-04577806
CAS:<p>PF-04577806: potent & selective PKC inhibitor, ATP competitive, blocks PKCα/βI/βII/γ/θ (IC50: 2.4-45.9 nM), may reverse diabetic retinal leakage.</p>Fórmula:C26H37N7O3Cor e Forma:SolidPeso molecular:495.628iRucaparib-AP6
CAS:<p>iRucaparib-AP6: a specific, non-trapping PARP1 degrader; inhibits the enzyme's activity and scaffolding.</p>Fórmula:C46H55FN6O11Pureza:98%Cor e Forma:SolidPeso molecular:886.96PROTAC BRD4 Degrader-5
CAS:<p>PROTAC BRD4 Degrader-5 is a PROTAC that degrades BRD4 in HER2 positive and negative breast cancer cell lines.</p>Fórmula:C50H62ClN9O8S2Cor e Forma:SolidPeso molecular:1016.67PROTAC BET degrader-3
<p>PROTAC BET Degrader-3 is a potent degrader OF BET based on PROTAC.</p>Fórmula:C53H64N12O9SPureza:98%Cor e Forma:SolidPeso molecular:1045.22PROTAC BRD4 Degrader-9
CAS:<p>PROTAC BRD4 Degrader-9 degrades BRD4 in PC3 cells; binds VHL and BRD4; DC50: STEAP1-0.86 nM, CLL1-7.6 nM.</p>Fórmula:C59H71F2N9O15S4Cor e Forma:SolidPeso molecular:1312.52-Methylquinazolin-4-ol
CAS:<p>Compound 1769-24-0 is a natural product for research related to life sciences. The catalog number is TPL0186 and the CAS number is 1769-24-0.</p>Fórmula:C9H8N2OPureza:99.98%Cor e Forma:SolidPeso molecular:160.17PROTAC BRD4 Degrader-32
<p>PROTACBRD4 Degrader-32 (Compound 22) is a potent BRD4 PROTAC degrader with a DC50 of 0.20 nM. It employs a unique carbon-carbon linker to connect the BRD4 binding domain with the CRBN binding domain, forming a ternary complex that induces BRD4 ubiquitination and facilitates proteasomal degradation. PROTACBRD4 Degrader-32 holds promise for research into BRD4-related cancers, such as hematological malignancies.</p>Fórmula:C42H42ClN5O5Cor e Forma:SolidPeso molecular:731.28745PROTAC SMARCA2/4-degrader-29
CAS:<p>PROTAC SMARCA2/4-degrader-29 (Compound I-279) serves as a degrader for the catalytic subunits SMARCA2 and SMARCA4 of the SWI/SNF complex. In A549 cells, this compound effectively degrades SMARCA2 with a DC50 value of less than 100 nM, and similarly degrades SMARCA4 in MV411 cells with a DC50 under 100 nM.</p>Fórmula:C44H51N11O4Cor e Forma:SolidPeso molecular:797.95VinSpinIn
CAS:<p>VinSpinIn is a probe for the Spin family proteins.</p>Fórmula:C42H58N8O4Cor e Forma:SolidPeso molecular:738.98EP300/CBP ligand 2
<p>EP300/CBP ligand 2 (compound S19) serves as a specific ligand for the bromodomain of CREB binding protein (CBP) and E1A-associated protein (EP300). It plays a critical role in PROTAC technology by acting as a target protein ligand. By linking to an E3 ubiquitin ligase ligand via the PROTAC Linker, it facilitates the synthesis of PROTAC molecules capable of targeted protein degradation. For instance, when EP300/CBP ligand 2 is connected to the conjugate (E3 ubiquitin enzyme ligand + Linker) Thalidomide-NH-C10-Boc, it results in the formation of the PROTAC molecule dCE-2.</p>Fórmula:C20H18N6OCor e Forma:SolidPeso molecular:358.4PROTAC SMARCA2/4-degrader-30
CAS:<p>Compound I-291, also known as PROTAC SMARCA2/4-degrader-30, targets the catalytic subunits of the SWI/SNF complex, specifically SMARCA2 and SMARCA4. It effectively degrades SMARCA2 in A549 and MV411 cells, as well as SMARCA4 in MV411 cells, with a degradation concentration (DC50) of less than 100 nM.</p>Fórmula:C44H51N11O4Cor e Forma:SolidPeso molecular:797.95PRO-HD1
<p>PRO-HD1, a PROTAC (proteolysis-targeting chimera) HDAC6 degrader, effectively degrades HDAC6 in A549 cells and inhibits Jurkat cell proliferation with an IC50</p>Pureza:98%Cor e Forma:Odour SolidBiguanide
CAS:<p>Biguanide can reduce oxidative stress in rats with hyperglycemia.</p>Fórmula:C2H7N5Cor e Forma:SolidPeso molecular:101.11Nicotinamide riboside tartrate
CAS:<p>NRT is an oral NAD+ precursor, boosts NAD+, activates SIRT1/3, provides vitamin B3, enhances metabolism, and may mitigate Alzheimer's.</p>Fórmula:C15H20N2O11Cor e Forma:SolidPeso molecular:404.33TAS-119
CAS:<p>TAS-119 (TAS-2104) is an orally available, selective and potent inhibitor of Aurora A with an IC50 of 1.0 nM.TAS-119 also inhibits Aurora B with an IC50 of 95</p>Fórmula:C23H22Cl2FN5O3Pureza:99.65%Cor e Forma:SolidPeso molecular:506.36TAT-cyclo-CLLFVY
CAS:<p>Blocks HIF-1α/β dimerization, not HIF-2α; suppresses VEGF, CAIX in cancer cells; antiangiogenic in HUVECs (IC50 = 1.3 μM).</p>Fórmula:C111H188N42O24S2Pureza:98%Cor e Forma:SolidPeso molecular:2559.1PROTAC SMARCA2/4-degrader-31
CAS:<p>PROTAC SMARCA2/4-degrader-31 (Compound I-280) serves as a degrader for the catalytic subunits SMARCA2 and SMARCA4 of the SWI/SNF complex. It effectively degrades SMARCA2 in A549 cells and SMARCA4 in MV411 cells, both with a degradation concentration (DC50) of less than 100 nM.</p>Fórmula:C44H51N11O4Cor e Forma:SolidPeso molecular:797.95AURKA against 1
<p>Compound Ac13, also termed AURKA against 1, acts as an inhibitor of the Aurora kinase (AURKA) with an IC50 of less than 0.5 nM, targeting the acetylation of endogenous lysine (K162) and exhibiting anti-tumor cell proliferation activity. The kinase activity of AURKA, acetylated at K162 and induced by AURKA against 1, is reversibly restored in HCT116 cells transfected with SIRT3.</p>Fórmula:C28H32FN9O2Cor e Forma:SolidPeso molecular:545.61PRO-HD3
<p>PRO-HD3 is a cell-specific, PROTAC-based degrader targeting HDAC6 [1].</p>Pureza:98%Cor e Forma:Odour SolidEPZ-719
CAS:<p>EPZ-719: Potent SETD2 inhibitor, IC50=0.005μM, high selectivity, potential for targeted epigenetic therapy.</p>Fórmula:C22H31FN4O3SCor e Forma:SolidPeso molecular:450.57SW2_152F
<p>SW2_152F: Potent CBX2 ChD inhibitor, Kd 80 nM, 24-1000x selective over other CBXs in vitro.</p>Fórmula:C45H62Cl3N7O8Cor e Forma:SolidPeso molecular:935.37MZP-55
CAS:<p>MZP-55 is a selective BRD3/4 degrader based on PROTAC technology(Brd4BD2 with Kd of 8 nM)</p>Fórmula:C57H70ClN7O10SPureza:98%Cor e Forma:SolidPeso molecular:1080.73PROTAC SMARCA2/4-degrader-27
CAS:<p>PROTAC SMARCA2/4-degrader-27 (PROTAC 2) serves as a targeted degrader, utilizing PROTAC technology to degrade both SMARCA2 and SMARCA4.</p>Fórmula:C49H58FN9O6SCor e Forma:SolidPeso molecular:920.11DS-103
<p>DS-103 is an HDAC inhibitor that targets HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 with IC50 values of 0.029, 0.123, 0.022, 0.367, and 9.26 μM, respectively. It also inhibits the malignant malaria parasite [Plasmodium falciparum 3D7] with an IC50 of 5.08 μM. In A2780 and Cal27 cells, DS-103 exhibits cytotoxicity with IC50 values of 1.48 μM and 1.47 μM, respectively, and reverses cisplatin resistance in these cells with IC50 values of 4.62 μM and 2.23 μM. DS-103 acts synergistically with cisplatin, enhancing apoptosis induced by cisplatin.</p>Fórmula:C28H33N5O3Cor e Forma:SolidPeso molecular:487.59PROTAC SMARCA2/4-degrader-26
<p>PROTAC SMARCA2/4-degrader-26 is a PROTAC targeting the SMARCA2/4 proteins. It is composed of the ligand for PROTAC targeting proteins, 2-(4-(3-Amino-6-(2-hydroxyphenyl)pyridazin-4-yl)piperazin-1-yl)acetic acid, an E3 ligase component (2S,4R)-4-Hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, and a PROTAC linker (S)-2-Amino-3,3-dimethylbutanoic acid. The coupled complex of the E3 ubiquitin ligase ligand + Linker is referred to as (S,R,S)-AHPC.</p>Fórmula:C38H47N9O5SCor e Forma:SolidPeso molecular:741.9SIRT1/2/3-IN-1
CAS:<p>Potent SIRT1/2/3-IN-1 inhibits SIRT1/2/3 with IC50: 0.54, 0.25, 0.72 μM; used in cancer research.</p>Fórmula:C46H63N9O8S2Cor e Forma:SolidPeso molecular:934.18HDAC6 ligand-3
<p>HDAC6ligand-3 serves as a ligand for HDAC6 and can be utilized as a target protein ligand in the synthesis of [PROTAC] HDAC6 degrader4.</p>Fórmula:C20H21N3O3Cor e Forma:SolidPeso molecular:351.399Antidiabetic agent 7
<p>Antidiabetic agent 7 (Compound 5m) functions as a potent hyperglycemia inhibitor. It effectively stimulates GLUT4 translocation in skeletal muscle cells by activating the AMPK-dependent pathway. Additionally, this compound is capable of reducing blood glucose levels and exhibits favorable pharmacokinetic properties. Antidiabetic agent 7 is suitable for research related to antihyperglycemic treatments.</p>Fórmula:C27H21Cl2N5O3Cor e Forma:SolidPeso molecular:534.39PRMT5 ligand 1
CAS:<p>PRMT5ligand 1 is a ligand of PRMT5, used as a target protein ligand in the synthesis of the PROTAC degrader MS4322.</p>Fórmula:C20H26N6O2Cor e Forma:SolidPeso molecular:382.459Lys-arg-ala-lys-ala-lys-thr-thr-lys-lys-arg
CAS:<p>Lys-arg-ala-lys-ala-lys-thr-thr-lys-lys-arg is a protein kinase C substrate.</p>Fórmula:C56H110N22O14Pureza:98%Cor e Forma:SolidPeso molecular:1315.61JAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Fórmula:C30H33FN4O3SCor e Forma:SolidPeso molecular:548.67BRD4 degrader AT1
CAS:<p>BRD4 degrader AT1 is a highly selective Brd4 degrader based on PROTAC technology, with a Kd of 44 nM for Brd4BD2 in cells.</p>Fórmula:C48H58ClN9O5S3Pureza:98%Cor e Forma:SolidPeso molecular:972.68TYD-68
<p>TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.</p>Cor e Forma:Odour SolidMS2133
<p>MS2133 is a DOT1L PROTAC degrader. It facilitates the ubiquitination and degradation of DOT1L in THP-1 and MV4-11 cells, with DC50 values of 56 nM and 25 nM, respectively, and reduces H3K79 methylation. MS2133 also inhibits the growth of MLL-r leukemia cells, demonstrating anticancer activity.</p>Fórmula:C58H66ClF3N14O11S2Cor e Forma:SolidPeso molecular:1290.41175Thalidomide-NH-CBP/p300 ligand 2
CAS:<p>Thalidomide-NH-CBP/p300 ligand 2 (P-007) is a PROTAC-based compound designed to degrade CBP and p300, acting as a functional antagonist (WO2020173440).</p>Fórmula:C48H57F2N11O6Cor e Forma:SolidPeso molecular:922.052Dihydrochlamydocin analog-1
CAS:<p>Dihydrochlamydocinanalog-1 (compound 2) is a Chlamydocin analog that inhibits the deacetylation of histone H4 peptides, with an IC50 of 30 nM.</p>Fórmula:C28H40N4O6Cor e Forma:SolidPeso molecular:528.64PROTAC HDAC6 degrader 4
<p>PROTAC HDAC6 degrader4 (Compound 17c) is a PROTAC that targets and degrades HDAC6, with a DC50 of 14 nM. It exhibits inhibitory activity against HDAC1, HDAC2, HDAC3, and HDAC6, with IC50 values of 2.2, 2.37, 0.61, and 0.295 μM, respectively. [Pink: ligand for target protein HDAC6 ligand-3; Black: linker; Blue: ligand for cereblon E3 ligase]</p>Fórmula:C39H42FN9O7Cor e Forma:SolidPeso molecular:767.81A-893
CAS:<p>A-893 is a cell-active inhibitor of Methyltransferase SMYD2 (IC 50 = 2.8 nM) .</p>Fórmula:C29H38Cl2N4O4Cor e Forma:SolidPeso molecular:577.54CARM1/IKZF3 ligand 1
<p>CARM1/IKZF3 ligand 1 functions as an inhibitor of CARM1 and serves as a target protein ligand for the synthesis of PROTAC CARM1/IKZF3 degrader-1.</p>Fórmula:C27H35ClN6O3Cor e Forma:SolidPeso molecular:527.06SJ10542
CAS:<p>SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.</p>Fórmula:C41H46N12O5SCor e Forma:SolidPeso molecular:818.95PROTAC CBP/P300 Degrader-1
CAS:<p>PROTAC CBP/P300 Degrader-1 effectively reduces cancer cell viability by degrading CBP/P300.</p>Fórmula:C46H53F2N11O6Cor e Forma:SolidPeso molecular:893.998HDAC11-IN-1
<p>HDAC11-IN-1 (Compound 14-NC6OH) is a macrocyclic inhibitor that selectively targets HDAC11 with a Ki of 40 nM. It demonstrates effective cell permeability and suppresses the expression of YAP1 and SOX2.</p>Fórmula:C43H63F3N6O6S2Cor e Forma:SolidPeso molecular:881.12SIRT1-IN-1
CAS:<p>SIRT1-IN-1 is a selective inhibitor of SIRT1 with an IC50 of 205 nM.Cost-effective and quality-assured.</p>Fórmula:C14H16N2OPureza:99.58%Cor e Forma:SolidPeso molecular:228.29(S,R,S)-AHPC-C5-COOH
CAS:<p>E3 ligase ligand-linker '(S,R,S)-AHPC-C5-COOH' for PROTACs, VH032 inhibits VHL/HIF-1α with 185 nM Kd, may aid anemia and ischemic disease research.</p>Fórmula:C29H42N4O5SPureza:98%Cor e Forma:SolidPeso molecular:558.73HDAC6 degrader-3
CAS:<p>HDAC6 degrader-3: potent, selective, degrades HDAC6 at 19.4 nM, weakens HDAC1 at 0.647 μM, induces α-tubulin hyperacetylation.</p>Fórmula:C41H41F4N7O11Cor e Forma:SolidPeso molecular:883.8JQ-1 (carboxylic acid)-NH-C2-NH-AMPRO-222
<p>JQ-1 (carboxylic acid)-NH-C2-NH-AMPRO-222 incorporates a BRD4 ligand and a PROTAC linker, and is used in the synthesis of PROTAC BRD4 Degrader-29.</p>Fórmula:C43H51ClN8O3S2Cor e Forma:SolidPeso molecular:827.5BTR2004
<p>BTR2004 is a selective PROTAC degrader targeting the BET family (BRD2/3/4) proteins. It facilitates the formation of a ternary complex with BRD proteins and KLHL20, leading to ubiquitination and proteasomal degradation via the UPS pathway. BTR2004 shows potential for research in PC3 prostate cancer and MDA-MB-231 breast cancer cell lines.</p>Cor e Forma:Odour SolidFluorescein-NAD+
<p>Fluorescein NAD+ is a non-radioactive PARP assay substrate, enabling direct enzyme measurement by fluorescence. Comes as 81μg in 250μl water.</p>Cor e Forma:SolidJAK3-IN-15
<p>JAK3-IN-15 (compound 22) is a JAK3 inhibitor that reduces the secretion of p-JAK3 induced by LPS. It is utilized in research for rheumatoid arthritis.</p>Cor e Forma:Odour SolidWDR5 ligand 2
CAS:<p>WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.</p>Fórmula:C29H31F3N4O4Cor e Forma:SolidPeso molecular:556.576
